Xcout Intel
Oncomatryx
Oncomatryx is a Spanish biopharmaceutical company headquartered in Derio, Basque Country, Spain. The firm pioneers targeted oncology therapeutics aimed at treating metastatic solid tumors and utilizes advanced computational approaches in its drug discovery pipeline.
Subscribe to see Oncomatryx’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Oncomatryx at a glance
Oncomatryx is a biotechnology company headquartered in Spain. Its most recent funding round, Growth, raised $27M in January 2025. Xcout tracks 6 named people at Oncomatryx, including Ignacio García (CMO).
Oncomatryx leadership
- Ignacio GarcíaCMO
- Myriam FabreCSO
- Pedro EsnaolaCPAO
- Laureano SimónCEO
- Manuel SanzCOO
- David A. RaksinVP Business Development
Oncomatryx funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Growth | $27M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Oncomatryx competitors
A few of Oncomatryx's closest competitors — see the full list of competitors and alternatives →
Oncodesign Precision Medicine is a biopharmaceutical company that develops innovative therapeutic and diagnostic solutions targeting treatment resistance, metastasis, and diseases such as oncology, inflammatory bowel disease, and Parkinson's disease. Utilizing proprietary technologies like OncoSNIPER, Nanocyclix, and PROMETHE, the company advances first-in-class and best-in-class precision medicine programs to serve patients, clinicians, and pharmaceutical partners.
Avammune Therapeutics is an R&D-driven drug discovery company headquartered in Philadelphia, Pennsylvania. The company focuses on developing novel, modality-agnostic immunotherapies and cancer therapies to address high unmet medical needs in hard-to-treat solid tumors.
Bakx Therapeutics, Inc. is a private biotechnology company founded in 2020 and based in New York, United States. The company specializes in pre-clinical oncology drug pipelines and novel therapeutics discovery.
Octant Bio is a biotechnology company that combines next-generation biology, chemistry, and computation to discover and develop precision small molecule therapeutics. The company targets complex cellular mechanisms to address genetic diseases, such as protein misfolding and mistrafficking across various therapeutic areas including genetic disorders, oncology, metabolism, and immunology.
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
Get Oncomatryx's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Oncomatryx in Xcout Intel
- 6 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access